Q4 Earnings Forecast for Insulet Issued By Leerink Partnrs

Insulet Corporation (NASDAQ:PODD) – Leerink Partnrs upped their Q4 2025 earnings estimates for shares of Insulet in a research note issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will earn $1.33 per share for the quarter, up from their prior forecast of $1.32. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the company posted $0.55 EPS. The company’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

A number of other research analysts also recently commented on the stock. Rothschild & Co Redburn upped their price objective on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Canaccord Genuity Group upped their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Oppenheimer upped their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Leerink Partners upped their price objective on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $348.05.

Insulet Trading Up 1.2%

NASDAQ PODD opened at $316.29 on Thursday. Insulet has a 12 month low of $226.50 and a 12 month high of $353.50. The company has a 50-day moving average of $325.99 and a 200-day moving average of $301.60. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market cap of $22.26 billion, a P/E ratio of 96.14, a P/E/G ratio of 2.61 and a beta of 1.40.

Institutional Trading of Insulet

Several large investors have recently bought and sold shares of the company. Avanza Fonder AB grew its position in Insulet by 23.8% in the third quarter. Avanza Fonder AB now owns 8,074 shares of the medical instruments supplier’s stock valued at $2,493,000 after acquiring an additional 1,552 shares in the last quarter. CWM LLC grew its position in Insulet by 7.8% in the third quarter. CWM LLC now owns 4,713 shares of the medical instruments supplier’s stock valued at $1,455,000 after acquiring an additional 343 shares in the last quarter. Brookstone Capital Management grew its position in Insulet by 191.2% in the third quarter. Brookstone Capital Management now owns 2,411 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 1,583 shares in the last quarter. Swedbank AB grew its position in Insulet by 6.9% in the third quarter. Swedbank AB now owns 77,488 shares of the medical instruments supplier’s stock valued at $23,923,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Net Worth Advisory Group acquired a new stake in Insulet in the third quarter valued at approximately $269,000.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.